PETMED EXPRESS INC PETS
PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, and as parent company of PetCareRx®, is a pioneer in pet healthcare, building a consumer-first digital platform in 1996 that transformed the way customers fulfill pet medications. Thirty years later, as a leading nationwide direct-to-consumer pet health and wellness retailer, the Company markets and sells directly to consumers through its websites (Petmeds.com and PetCareRx.com), customer contact centers, and mobile applications (iOS and Android). The Company provides access to top branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter (OTC) health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and personalized AutoShip capabilities. Our digital platform offers pet healthcare solutions for a broad range of chronic conditions, including those related to allergies, arthritis, anxiety, kidneys, hyperthyroidism, and others for cats, dogs, and horses. We also offer access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. PetMeds and PetCareRx receive the pet's order through our websites and mobile applications and connect to the customer's licensed veterinarian for prescription approval. Through our content website, pethealthmd.com, consumers can access educational articles for any health-related questions regarding their pets. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service. For 30 years, PetMeds has been a trusted partner in pet health, delivering expert-backed products and pharmacy care to families.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $179.0M | $227.0M | $274.1M | $247.6M | $272.3M | $303.6M | $284.1M | $283.4M | $273.8M | $249.2M |
| Cost of revenue | — | $157.8M | $189.3M | $171.1M | $195.3M | $219.3M | $202.9M | $188.1M | $176.0M | $169.9M |
| Gross profit | $50.2M | $69.1M | $84.8M | $76.5M | $76.9M | $84.3M | $81.2M | $95.3M | $97.8M | $79.3M |
| SG&A | $50.7M | $38.6M | $55.2M | $41.7M | $31.1M | $29.7M | $25.3M | $24.8M | $24.3M | $22.8M |
| Total operating expenses | $108.9M | $70.7M | $92.9M | $70.5M | $52.7M | $53.8M | $50.3M | $49.1M | $45.7M | $41.8M |
| Operating income | -$58.7M | -$1.5M | -$8.2M | $6.1M | $24.3M | $30.5M | $31.0M | $46.2M | $52.1M | $37.5M |
| Pre-tax income | -$57.4M | -$587.0K | -$6.3M | $7.4M | $24.2M | $30.9M | $33.9M | $49.1M | $53.8M | $37.9M |
| Income tax | $73.0K | $5.7M | $1.2M | $2.3M | $5.5M | $7.0M | $8.0M | $11.4M | $16.5M | $14.1M |
| Net income | -$57.3M | -$6.3M | -$7.5M | $5.1M | $18.7M | $23.9M | $25.9M | $37.7M | $37.3M | $23.8M |
| EPS, basic | -2.74 | -0.30 | -0.37 | 0.25 | 0.93 | 1.19 | 1.29 | 1.84 | 1.83 | 1.18 |
| EPS, diluted | -2.74 | -0.30 | -0.37 | 0.25 | 0.92 | 1.19 | 1.29 | 1.84 | 1.82 | 1.17 |
| Shares, diluted (wtd. avg.) | $20.9M | $20.6M | $20.4M | $20.3M | $20.4M | $20.1M | $20.1M | $20.5M | $20.4M | $20.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.4M | $54.7M | $55.3M | $104.1M | $111.1M | $118.7M | $103.8M | $100.5M | $77.9M | $58.7M |
| Receivables | $1.9M | $2.3M | $3.3M | $1.7M | $1.9M | $2.6M | $3.8M | $2.5M | $2.3M | $1.8M |
| Inventory | $13.6M | $16.2M | $28.6M | — | — | — | — | — | — | — |
| Total current assets | $43.6M | $78.9M | $93.6M | $130.4M | $151.0M | $161.2M | $129.0M | $126.4M | $105.2M | $81.8M |
| Property, plant and equipment | $26.3M | $28.9M | $26.7M | $26.2M | $24.5M | $25.4M | $25.4M | $27.1M | $28.7M | $30.2M |
| Goodwill | $0 | $26.7M | $26.7M | $0 | — | — | — | — | — | — |
| Other intangibles | $5.5M | $8.0M | $11.2M | $860.0K | $860.0K | $860.0K | $860.0K | $860.0K | $860.0K | $860.0K |
| Total assets | $81.2M | $148.7M | $169.9M | $167.5M | $179.7M | $187.5M | $155.3M | $154.4M | $134.8M | $112.8M |
| Accounts payable | $20.9M | $23.6M | $37.0M | $25.2M | $27.5M | $39.5M | $19.7M | $16.3M | $15.3M | $15.2M |
| Total current liabilities | $52.0M | $62.8M | $72.2M | $57.5M | $56.2M | $44.9M | $24.3M | $18.6M | $18.1M | $18.4M |
| Total liabilities | $52.3M | $63.6M | $73.2M | $57.5M | $56.2M | $46.2M | $25.3M | $19.7M | $19.1M | $19.4M |
| Retained earnings | $9.3M | $66.5M | $71.6M | $91.7M | $115.3M | $134.1M | $126.2M | $122.2M | $106.3M | $86.5M |
| Total equity | $28.9M | $85.1M | $96.7M | $110.0M | $123.5M | $124.9M | $120.3M | $134.7M | $115.7M | $93.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.4M | $4.7M | $4.3M | $27.8M | $18.5M | $40.1M | $38.8M | $45.1M | $37.4M | $47.2M |
| Depreciation and amortisation | $9.4M | $7.0M | $7.1M | $3.5M | $2.7M | $2.4M | $2.3M | $2.2M | $2.1M | $1.4M |
| Stock-based compensation | $1.4M | -$6.6M | $6.9M | $6.6M | $4.5M | $3.3M | $2.8M | $3.1M | $2.6M | $1.9M |
| Capital expenditure | $4.6M | $5.1M | $4.5M | $5.3M | $1.8M | $2.4M | $2.3M | $620.0K | $703.0K | $10.6M |
| Investing cash flow | -$4.6M | -$5.1M | -$40.7M | -$10.3M | -$1.8M | -$2.4M | -$2.3M | -$620.0K | -$703.0K | -$10.6M |
| Financing cash flow | -$299.0K | -$181.0K | -$12.4M | -$24.5M | -$24.4M | -$22.7M | -$33.3M | -$21.9M | -$17.5M | -$15.5M |
| Dividends paid | $21.0K | $181.0K | $12.4M | $24.5M | $24.4M | $22.7M | $21.8M | $21.9M | $17.5M | $15.5M |
| Buybacks | — | — | — | — | $0 | $0 | $11.5M | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001040130-26-000023.
Others in SIC 5912
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CVS | CVS HEALTH Corp | $123.73B | 69.6x | 7.8% |
| YI | 111, Inc. | — | — | -9.0% |
| GRDN | Guardian Pharmacy Services, Inc. | — | — | 17.9% |
| RDGT | Ridgetech Inc. | — | — | 10.2% |